Genentech’s BD head spotlights neuroscience pipeline

April 27, 2017 Christoph Graener

Thomas Zioncheck, business development executive for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company’s early-stage partnering strategy and R&D goals outside of oncology. Zioncheck discusses Genentech’s multiple sclerosis and Alzheimer’s portfolios, therapy areas not as widely promoted as the company’s active and expansive immuno-oncology pipeline. Genentech’s BD head also highlights the company’s early-stage development program for a novel amyotrophic lateral sclerosis (ALS) therapy, a disease that has garnered more attention since the widely-shared ALS Ice Bucket Challenge—a social media fundraising and awareness campaign. The company is developing RG6000, a dual leucine zipper kinase (DLK) inhibitor, for the treatment of ALS. The drug, a new molecular entity, is currently in Phase I trials.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Thomas F. Zioncheck – Global Head, Business Development for Neuroscience,
Ophthalmology, and Research Tools and Technologies, Genentech

Previous Article
Avir BD execs on innovative meds for Canadians

Avir Pharma's business development associate Vanessa Fortin and VP of business development Kaled Kadri talk...

Next Article
Ergomed’s evolution and risk-sharing business model in practice

Andrew Mackie, chief business officer of Ergomed, talks to Scrip about the company's transformation from a ...